Introducing NephJC’s brand new editorial internship class of 2026-2027

This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease

This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

2025 was rich in successful stories. Here are the top 10 that impressed our audience.

En pacientes con lesión renal aguda en diálisis, se evaluó si una estrategia más conservadora impacta en la recuperación renal. ¿Será que menos es más? Únete a la discusión del ensayo clínico LIBERATE...

This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

Curious how n-3 PUFAs may cut serious cardiovascular events in dialysis? 🐟 A big signal, a big dose, and a big discussion ahead — don’t miss this #NephJC! Check out the VA made by our master Brian...

We have a patient perspective on the new IgA Guidelines and what it means to live with IgA in these times.

This cross-sectional study aims to determine whether and when medicines receive market authorization in the countries where they are tested for US Food and Drug Administration approval, as well as tre...

This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy

Atacicept, BAFF/APRIL inhibition in IgAN

ORIGIN-3 ha llegado a NephJC con atacicept en NIgA. Un paso sólido hacia una terapia dirigida anti BAFF/APRIL, que aborda la fisiopatología desde su origen. ¡Las señales tempranas son prometedoras! R...

This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.

KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection. Check out the visual abstract created by Natalia Nombera

SOUTH SAN FRANCISCO, Calif., October 20, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva...

Effect of a very low protein diet on outcome: long-term follow-up.This is the long-term follow-up of the B group from the original MDRD study.Enrollment criteria:Age: 18-70Abnormal Cr 1.2-7 women 1…

We like protein, or do we? Low protein, high protein, supplements…what’s a nephrologist to do?

This week, we will discuss an old dilemma in nephrology. To restrict or supplement the proteins? Premise: advanced CKD and dialysis.

We like protein, or do we? Low protein, high protein, supplements…what’s a nephrologist to do?

Help keep NephJC a vital, original, and unbiased source of medical education.